Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 19/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822634 | 0.90 | ACVRL1 (0.42) | ACVRL1PIK3CD | |
| SCHEMBL16698811 | 0.83 | ACVRL1 (0.39) | ACVRL1PIK3CD | |
| SCHEMBL23959982 | 0.82 | ACVRL1 (0.42) | ACVRL1PIK3CD | |
| SCHEMBL16699309 | 0.81 | POLRMT (0.41) | ACVRL1PIK3CD | |
| SCHEMBL15259032 | 0.81 | STING1 (0.32) | ACVRL1PIK3CD | |
| SCHEMBL20960073 | 0.80 | POLRMT (0.46) | ACVRL1PIK3CD | |
| SCHEMBL16699053 | 0.80 | POLRMT (0.40) | ACVRL1PIK3CD | |
| SCHEMBL20756371 | 0.80 | POLRMT (0.40) | ACVRL1PIK3CD | |
| Phosphoric Acid SCHEMBL16701315 | 0.79 | PIK3CD (0.36) | ACVRL1PIK3CD | |
| SCHEMBL23959981 | 0.78 | ACVRL1 (0.41) | ACVRL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190055253-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-02-21 | — | — | US | disclosed |
| US-9701682-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | SYNJ1, SARS1, SYNJ2 | ACVRL1 277/4885PIK3CD 4642/4885 |
| US-20190055253-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | ACVRL1 277/4885PIK3CD 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.